Spots Global Cancer Trial Database for Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
Official Title: Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study
Study ID: NCT05462613
Conditions
Study Description
Brief Summary: This study evaluates the interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin as a 2 months induction therapy before chemotherapy initiation in the second-line metastatic colorectal carcinoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
CHU de Besançon, Besançon, , France
Hôpital Henri Mondor, Créteil, , France
Centre Georges François Leclerc, Dijon, , France
Centre Léon Bérard, Lyon, , France
Hôpital Privé Jean Mermoz, Lyon, , France
Hôpital Nord Franche Comté, Montbeliard, , France
Groupe hospitalier de la région de Mulhouse et Sud Alsace, Mulhouse, , France
Hôpital Européen Georges Pompidou, Paris, , France
Hôpital la Pitié-Salpétrière, Paris, , France
Hôpital Saint antoine, Paris, , France
Institut Mutualiste Montsouris, Paris, , France
CHU de Reims - Hôpital Robert Debré, Reims, , France
Hôpital FOCH, Suresnes, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
